Ortho Evra Related Published Studies
Well-designed clinical trials related to Ortho Evra (Norelgestromin / Estradiol Transdermal)
Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. [2005.06]
Well-designed clinical trials possibly related to Ortho Evra (Norelgestromin / Estradiol Transdermal)
Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. [2008.02]
Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. [2006.10]
Suppression of estrogen-withdrawal headache with extended transdermal contraception. [2005.06]
Effect of oral versus transdermal steroidal contraceptives on androgenic markers. [2005.06]
Other research related to Ortho Evra (Norelgestromin / Estradiol Transdermal)
Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy. [2009.06.30]
Effect of the ethinylestradiol/norelgestromin contraceptive patch on body composition. Results of bioelectrical impedance analysis in a population of Italian women. [2008.08.26]
Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. [2005.04]
Other possibly related research studies
Comparing patient telephone callback rates for different hormonal birth control delivery systems. [2006.11]
Advances in hormonal contraception. [2006.10]
[Safety evaluation of a transdermal contraceptive system with an oral contraceptive] [2005.11]
Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. [2006.03]
Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study. [2005.04]
Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. [2007.02]
The contraceptive patch in relation to ischemic stroke and acute myocardial infarction. [2007.02]
Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. [2007.04]
Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch? [2007.04]
Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs. [2007.04.02]
Transdermal hormonal contraception: benefits and risks. [2007.08]
Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs. [2007.04.02]
A clinical study of transdermal contraceptive patch in Thai women. [2006.10]
Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. [2007.07]
Oral and transdermal hormonal contraception in women after kidney transplantation. [2007.11]
The transdermal contraceptive patch: an updated review of the literature. [2007.12]
A clinical study of transdermal contraceptive patch in Thai adolescence women. [2008.02]
Trends in prescribing patterns of hormonal contraceptives for adolescents. [2008.04]
Contraception in hereditary angioedema. [2008.11]
The risk of unintended pregnancies in users of the contraceptive patch compared to users of oral contraceptives in the UK General Practice Research Database. [2009.08]
Confronting the legal risks of prescribing the contraceptive patch with ongoing litigation. [2009.03]
|
